Focused on the development of biomedical ultrasound for cardiovascular disease, neuroscience, and cancer, the first technology research accelerator (ART), launched by Inserm in 2016, has already succeeded in developing ten or so innovative technologies. These technologies offer new prospects, both in fundamental and clinical research.

QuiTuSais
Mon 01 Apr 2019 – 12:33